% | $
Quotes you view appear here for quick access.

Neuralstem, Inc. Message Board

investorgold 65 posts  |  Last Activity: Jul 6, 2016 10:07 AM Member since: Mar 10, 1999
  • investorgold by investorgold Jul 6, 2016 10:07 AM Flag

    Dollar 1.000 tradet today retailer selling and going out see you next year !!!

  • think about as Investor or Company !!!

    Sentiment: Strong Buy

  • Reply to

    take over is possible !!!

    by investorgold Jun 27, 2016 10:39 AM
    investorgold investorgold Jun 28, 2016 2:09 AM Flag

    yes to much Shares but the game is not over !!!

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 27, 2016 10:39 AM Flag

    why not !!!

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 22, 2016 10:22 AM Flag

    3,100 0.3300
    100 0.3290
    200 0.3270
    200 0.3260
    2,100 0.3182


    25,127 0.3130
    10,000 0.3120
    35,000 0.3100
    200 0.3060
    50,000 0.3010

    Sentiment: Strong Buy

  • Reply to

    pre-market high 0.40 cent !!!

    by investorgold Jun 21, 2016 10:12 AM
    investorgold investorgold Jun 21, 2016 10:23 AM Flag

    we going in red today again !!

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 21, 2016 10:12 AM Flag

    know .33 Cent no big buyer more seller !!!

    Sentiment: Strong Buy

  • ok I see

    Sentiment: Strong Buy

  • investorgold investorgold Jun 20, 2016 10:19 AM Flag

    the best is you sell your Shares if you know all this !!!

    Sentiment: Strong Buy

  • 7,000 200.0000
    400 2.5000
    1,000 1.1600
    90,000 0.9900
    5,850 0.3900

    Sentiment: Strong Buy

  • investorgold investorgold Jun 20, 2016 8:41 AM Flag

    you have no Shares and R/S is a Long way to go next year if we are still under 1 Dollar !!

    Sentiment: Strong Buy

  • Reply to

    W h a t `s going o n !!!!!!

    by investorgold Jun 18, 2016 4:46 AM
    investorgold investorgold Jun 19, 2016 5:07 AM Flag

    you are an idiot go away to stem loser !!!!!!

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 18, 2016 4:46 AM Flag

    BlackRock Fund Advisors reduced its stake in shares of Neuralstem, Inc. (NASDAQ:CUR) by 6.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,249 shares of the company’s stock after selling 12,220 shares during the period. BlackRock Fund Advisors owned approximately 0.19% of Neuralstem worth $129,000 as of its most recent SEC filing.

    Shares of Neuralstem, Inc. (NASDAQ:CUR) opened at 0.30 on Friday. The company’s market capitalization is $27.61 million. Neuralstem, Inc. has a 1-year low of $0.30 and a 1-year high of $2.26. The company has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.74.

    Neuralstem (NASDAQ:CUR) last issued its earnings results on Monday, May 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts anticipate that Neuralstem, Inc. will post ($0.21) EPS for the current year.

    Separately, Brean Capital restated a “buy” rating and set a $8.00 price objective on shares of Neuralstem in a research report on Saturday, February 20th.

    Neuralstem, Inc (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord, thus enabling the generation of physiologically relevant human neurons of all types.

    Want to see what other hedge funds are holding CUR? Visit to get the latest 13F filings and insider trades for Neuralstem, Inc. (NASDAQ:CUR).

    Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with's FREE daily email newsletter.

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 17, 2016 4:08 AM Flag

    The following excerpt is from the company's SEC filing.

    I hereby tender my resignation as a member of the board of directors of Neuralstem, Inc. the “Company”). My resignation is effective immediately. My resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. I extend my best wishes to the Company, its directors, officers and employees.

    Yours Truly,

    /s/ I. Richard Garr

    June 16, 2016

    The above information was disclosed in a filing to the SEC. To see the filing, click here.

    To receive a free e-mail notification whenever Neuralstem makes a similar move, sign up!

    Other recent filings from the company include the following:

    Sentiment: Strong Buy

  • investorgold investorgold Jun 17, 2016 3:19 AM Flag

    I will lose a lot of Money too if it fails but I m still Holding my big position

    Sentiment: Strong Buy

  • Reply to

    Is this a joke !!!!

    by investorgold Jun 14, 2016 10:11 AM
    investorgold investorgold Jun 14, 2016 10:17 AM Flag

    67 Institutional Holders
    14,458,305 Total Shares Held

  • investorgold by investorgold Jun 14, 2016 10:11 AM Flag

    Brean Capital’s healthcare analyst Jonathan Aschoff came out with a commentary on Neuralstem, Inc. (NASDAQ:CUR), after the company presented an updated analysis of its last completed NSI-566 Phase 1 and 2 trials in ALS at the ANA meeting in Chicago Monday.

    Aschoff wrote, “A total of 24 of the 30 ALS patients participating in the trials were discussed in the presentation, with safety of the maximum tolerated stem cell dosage being the primary endpoint. The escalating doses were generally well tolerated, with the most common AE being post-operative pain. Secondary endpoints included forced vital capacity (FVC), ALS Functional Rating Scalerevised (ALSFRSr), and assessment of grip strength, respiratory functions and muscle strength.”

    “We continue to expect Neuralstem to adopt an enriched enrollment and to recruit healthier patients that are more likely to benefit from NSI-566 therapy. Beyond ALS, Neuralstem is evaluating NSI-566 for cSCI and ischemic stroke in Phase 1/2 trials, which represent potential upside to our valuation,” the analyst concluded.

    Aschoff rates Neuralstem shares a Buy, with a price target of $8, which implies an upside of 556% from current levels.

    According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a total average return of -7.3% and a 32.8% success rate. Aschoff has a -38.2% average return when recommending CUR, and is ranked #3684 out of 3754 analysts.

    Out of the 5 analysts polled by TipRanks, 3 rate Neuralstem stock a Buy, 1 rates the stock a Hold and 1 recommends a Sell. With a return potential of 335%, the stock’s consensus target price stands at $5.31.

  • Shorts not covert !!!! remember the day volume

    May 31, 2016 0.35 0.36 0.33 0.34 848,700 0.34
    May 27, 2016 0.37 0.37 0.34 0.34 1,114,900 0.34
    May 26, 2016 0.34 0.38 0.33 0.36 3,476,000 0.36

    Sentiment: Strong Buy

  • investorgold by investorgold Jun 9, 2016 9:44 AM Flag

    Neural stem cell transplants show promise in Parkinson’s disease

    8 June 2016 • Author: Victoria White, Digital Content Producer

    A team of researchers testing the potential of cell therapy for treating Parkinson’s disease (PD) has found that grafting human parthenogenetic stem cell-derived neural stem cells (hpNSCs) into non-human primates modelled with PD promoted behavioural recovery, increased dopamine concentrations in the brain, and induced the expression of beneficial genes and pathways when compared to control animals not transplanted with stem cells.


    The researchers also reported that the intracerebral injection and transplantation of hpNSCs was safe and well-tolerated for the two transplantation test animal groups with moderate to severe PD symptoms.

    PD is characterised by a profound loss of function of the brain’s basal ganglia, resulting in a loss of dopamine neurons. While there are drugs, such as Levodopa (L-DOPA), that increase dopamine function and provide temporary clinical improvement in some symptoms, the drug can also cause serious side effects. Cell-based therapies are offering promise as an alternative. Experiments using stem cells have offered benefits in preclinical studies, but have also provided “a wide variety of patient outcomes,” said the researchers.

    hpNSCs may open up “a new avenue”

    This study used hpNSCs because the cells demonstrate characteristics of human embryonic stem cells, but are not sourced from viable embryos, which may be destroyed in the process. The researchers said that their previous studies with hpNSCs had shown that the cells could also be “chemically directed” to differentiate into multipotent neural stem cells and were able to be frozen for future use.

    While the study was designed to determine whether the test animals showed greater improvement than the control group, researchers added that a longer outcome period than 12 months may have demonstrated continued improvement and divergence from controls.

    “The use of neural stem cells derived from human parthenogenic cells may be a new avenue for treating a variety of conditions,” said Dr Paul Sanberg, distinguished university professor at the University of South Florida in Tampa Florida. “The study showed evidence of safety in using these cells, which is an improvement upon previous stem cell therapies that have shown some lineages may result in tumour formation. A follow-up study that further assesses the clinical potential of this approach for functional improvement may prove promising in future treatments for Parkinson’s disease.”

    Related topics
    Parkinson's disease
    Stem Cells

    Related stories

    CiRA and Takeda to collaborate on iPS Cell ResearchCiRA and Takeda to collaborate on iPS Cell Research

    Scientists identify key receptors behind development of acute myeloid leukaemiaScientists identify key receptors behind development of acute myeloid leukaemia

    Stem cell company DefininGEN raises £1.5m in follow-on fundingStem cell company DefininGEN raises £1.5m in follow-on funding

    Also see...


    Leaving EU could be a setback for Life Sciences in the UK


    JLINX: a first of its kind European incubation model to catalyse scientific innovation

    Leave a reply

    Name (required)

    Sentiment: Strong Buy

0.291-0.007(-2.35%)Oct 21 3:59 PMEDT